Q2 EPS Estimate for Elevation Oncology Decreased by Analyst

Elevation Oncology, Inc. (NASDAQ:ELEV) – Equities researchers at Leerink Partnrs dropped their Q2 2025 EPS estimates for shares of Elevation Oncology in a note issued to investors on Monday, June 9th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.36) per share for the quarter, down from their previous forecast of ($0.28). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s FY2025 earnings at ($0.79) EPS.

Elevation Oncology (NASDAQ:ELEV) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04).

ELEV has been the subject of several other reports. TD Cowen lowered shares of Elevation Oncology from a “strong-buy” rating to a “hold” rating in a report on Monday, June 9th. HC Wainwright lowered shares of Elevation Oncology from a “strong-buy” rating to a “neutral” rating in a report on Tuesday. William Blair lowered shares of Elevation Oncology from a “strong-buy” rating to a “hold” rating in a report on Monday, June 9th. Citigroup lowered shares of Elevation Oncology to a “market perform” rating in a report on Friday, March 21st. Finally, Citizens Jmp lowered shares of Elevation Oncology from an “outperform” rating to a “market perform” rating in a report on Friday, March 21st. Eleven equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.39.

Elevation Oncology Price Performance

Shares of ELEV stock opened at $0.38 on Thursday. The firm has a market cap of $22.61 million, a P/E ratio of -0.47 and a beta of 1.43. The company has a debt-to-equity ratio of 0.45, a current ratio of 17.77 and a quick ratio of 17.77. Elevation Oncology has a 1-year low of $0.22 and a 1-year high of $3.36. The firm has a fifty day moving average of $0.33 and a two-hundred day moving average of $0.49.

Institutional Trading of Elevation Oncology

Several hedge funds have recently bought and sold shares of the company. BML Capital Management LLC bought a new stake in Elevation Oncology in the 1st quarter valued at about $1,526,000. Geode Capital Management LLC lifted its position in Elevation Oncology by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 1,157,572 shares of the company’s stock valued at $651,000 after purchasing an additional 47,487 shares during the last quarter. Millennium Management LLC lifted its position in Elevation Oncology by 3.9% in the 4th quarter. Millennium Management LLC now owns 815,916 shares of the company’s stock valued at $459,000 after purchasing an additional 30,466 shares during the last quarter. Northern Trust Corp lifted its position in Elevation Oncology by 15.9% in the 4th quarter. Northern Trust Corp now owns 432,620 shares of the company’s stock valued at $243,000 after purchasing an additional 59,392 shares during the last quarter. Finally, Allostery Investments LP bought a new stake in Elevation Oncology in the 4th quarter valued at about $243,000. 83.70% of the stock is currently owned by institutional investors.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.